Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Steven Dunder (NPI 1346264546)

Field	Value
Entity Type	Individual
Organization	Steven Dunder
Address	4101 Tiger Lily Rd Ste 100
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 27, 2006

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider bills almost exclusively to Medicare with Total Medicare revenue of $1.7M and no Medicaid billing on file, making the practice effectively single‑payer for the datasets available. That concentration means Medicare reimbursement trends, policy changes, or price edits to high‑cost oncology drugs will have outsized impact on the provider's topline in this dataset.

Revenue is highly concentrated in a small set of oncology drugs: the precomputed top‑3 Medicare codes (J9299, J9271, J9144) account for 61.1% of the provider's total Medicare revenue. Individually those codes are J9299 $466.6K (29.2%), J9271 $283.8K (17.8%), and J9144 $225.7K (14.1%), so a few high‑cost infusions drive the majority of reported Medicare dollars.

The claim mix is consistent with an infusion‑focused hematology/oncology practice: high revenue items are oncology immunotherapies and monoclonal antibodies (J9299 nivolumab, J9271 pembrolizumab, J9144 daratumumab), supported by chemotherapy administration codes (96413, 96365, G0498) and supportive agents (J0897 denosumab, J2506 pegfilgrastim). This pattern indicates the operation likely centers on drug administration and associated outpatient infusion services rather than primary care or procedure‑only specialties.

Competitive standing on the headline drugs is modest rather than dominant: J9299 ranks #174 of 505 providers nationally (65th percentile; typical, unremarkable volume for this code), indicating moderate national activity for nivolumab. By contrast J9271 (pembrolizumab) ranks #1566 of 1841 (14th percentile; typical, unremarkable volume) and J9144 (daratumumab) ranks #433 of 615 (28th percentile; typical, unremarkable volume), so the provider is a meaningful but not leading participant in these drug markets.

Several high‑frequency support codes point to a busy outpatient infusion workflow: 85025 (CBC) contributes $12.4K and ranks in the 96th percentile for volume (typical, unremarkable volume), 80053 (CMP) contributes $10.8K and ranks in the 95th percentile (typical, unremarkable volume), and 36415 (venipuncture) contributes $10.4K and ranks in the 98th percentile (typical, unremarkable volume). Together these lab and access codes reinforce that the revenue profile is driven by routine monitoring and nursing/infusion throughput that accompanies high volumes of injectable therapies.

Imaging and diagnostic services are a secondary but nontrivial revenue stream: fused PET/CT (78815) accounts for $84.9K (5.3% of Medicare revenue) and A9552 FDG doses add $10.8K, with 78815 ranking #2581 of 6566 (60th percentile; typical, unremarkable volume). This suggests either on‑site imaging capacity or close operational integration with imaging centers to support staging and treatment response assessment for oncology patients.

The provider shows a long tenure in Medicare billing: NPI enumerated 2006-07-27 (~20 years ago), indicating an established billing history and likely stable referral relationships that support ongoing infusion and oncology services. That longevity, combined with the concentrated drug mix, suggests entrenched operational processes for outpatient cancer therapy delivery.

From a payer‑risk and operational perspective, dependence on a few high‑revenue injectable drugs creates exposure to formulary changes and reimbursement edits for those J‑codes, while the absence of Medicaid activity means limited diversification by payer type in this dataset. Analysts should treat this profile as a Medicare‑centric infusion practice with concentrated drug revenue and typical national volumes for its headline agents rather than as a broad multisite or dual‑payer operation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

75 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	19,440	$20	$466.6K
J9271	Injection, pembrolizumab, 1 mg	6,600	$40	$283.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,940	$40	$225.7K
J0897	Injection, denosumab, 1 mg	10,080	$20	$181.4K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,090	$84.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	580	$90	$50.9K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	500	$80	$42.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	370	$90	$33.9K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	20	$1,090	$26.2K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	4,340	$10	$26K

Showing 1–10 of 75

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Steven Dunder — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

75 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	26	30	14,400	$40	$671.6K
J9299	6	10	19,300	$20	$444.5K
J9144	9	10	10,440	$40	$434.6K
J0897	12	200	2,040	$20	$62.7K
J2506	5	20	460	$90	$40.5K
78815	23	60	70	$380	$32.7K
Q5116	2	10	1,400	$20	$30.7K
J1439	17	30	25,880	$1	$26.4K
J9217	45	50	110	$130	$20.6K
J0885	3	10	3,180	$10	$19.2K

Showing 1–10 of 75

Related Providers

Other providers that share a Tax Identification Number (TIN) with Steven Dunder, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Samuel Jurca	ID	Family Medicine Physician	$24M	$0
Richard Lane	TX	Retina Specialist (Ophthalmology) Physician	$4.8M	$0
Thomas Oei	TX	Retina Specialist (Ophthalmology) Physician	$4.3M	$0
Ronald Drengler	TX	Medical Oncology Physician	$3.8M	$0
Jose Martinez	TX	Ophthalmology Physician	$3.8M	$0
Jeremiah Brown	TX	Retina Specialist (Ophthalmology) Physician	$3.7M	$0
Sarah Holy	TX	Retina Specialist (Ophthalmology) Physician	$3.5M	$0
Richard Kinsey	TN	Anatomic Pathology & Clinical Pathology Physician	$3.3M	$147.3K

Nearby Providers

Other providers in the same ZIP code as Steven Dunder, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Rick Chatwell	NE	Rheumatology Physician	$3.5M	$0
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Scott Mcham	NE	Hematology & Oncology Physician	$1.9M	$0
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0

Steven Dunder — Billing Profile & Reimbursement Data

Sign up for Steven Dunder — Billing Profile & Reimbursement Data policy alerts

Steven Dunder — Billing Profile & Reimbursement Data

Sign up for Steven Dunder — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References